Home > Clinics and Services > Clinics and Departments > Pediatric Oncology > Cancer Clinical Trials
Pediatric Oncology Cancer Clinical Trials

US News and World Report Ranking Badge
Pediatric Oncology Cancer Clinical Trials

Cancer Clinical Trials


The team at Children's Mercy Kansas City conducts ongoing clinical trials that lead to the discovery of new cancer-fighting drugs, along with giving pediatric cancer patients more innovative treatment options. The Experimental Therapeutics in Cancer Program leads the area with expertise in pediatric clinical trials.

Active Phase 1 and Phase 2 Trials

Our staff is led by a physician who is board-certified in hematology/oncology and pharmacology. Staff members include nurse practitioners and research nurses experienced in treating pediatric cancer patients. Our doctors and research scientists continue to apply knowledge from research studies directly to improving pediatric cancer care. The program is currently involved with more than 15 studies of phase I and phase II cancer drugs. 

Our extensive track record in pharmacology clinical trials research includes leadership in pediatric labeling for 35 separate medications since the Best Pharmaceuticals for Children Act of 2002. The program has been selected to serve as the clinical pharmacology core for the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) and the Neuroblastoma Medulloblastoma Translational Research Consortium.

Each year, the Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation at Children’s Mercy Kansas City provides comprehensive care to nearly 2,000 children with childhood cancers, sickle cell disease, hemophilia and other blood disorders, with survival rates frequently above national averages. 

Our commitment to clinical research and innovation has helped us earn recognition as one of the top cancer programs for kids in the nation by U.S. News and World Report. Children’s Mercy also has received accreditation from the American College of Surgeons Commission on Cancer and the Foundation for Accreditation of Cellular Therapy. 

 

Copyright © 2017 Children's Mercy Kansas City